Novartis partners with small North Carolina biotech to make its biologics more 'convenient'

Kyle LaHucik

Senior Reporter

Novartis announced a collaboration on Wednesday with a small North Carolina biotech whose technology could help turn more of the Swiss pharma giant’s infused drugs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis partners with small North Carolina biotech to make its biologics more 'convenient'

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Doug Williams returns with a ‘FIT’ bet on CAR-Ts; Biogen appoints Mene Pangalos to board

No­var­tis part­ners with small North Car­oli­na biotech to make its bi­o­log­ics more 'con­ve­nien­t'

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Novartis partners with small North Carolina biotech to make its biologics more 'convenient'